Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Ádám Póti 1, Hella Gyergyák 1, Eszter Németh 1, Orsolya Rusz 1,2, Szilárd Tóth 1, Csenger Kovács-házi 1, Dan Chen 1, Bernadett Szikriszt 1, Sándor Spisák 3,4, Shunichi Takeda 5, Gergely Szakács 1,6, Zoltan Szallas 7,8,9,10, Andrea L. Richardson 11* and Dávid Szüts 1*

Abstract

Background: Homologous recombination (HR) repair deficiency arising from defects in BRCA1 or BRCA2 is associated with characteristic patterns of somatic mutations. In this genetic study, we ask whether inactivating mutations in further genes of the HR pathway or the DNA damage checkpoint also give rise to somatic mutation patterns that can be used for treatment prediction.

Results: Using whole genome sequencing of an isogenic knockout cell line panel, we find a universal HR deficiency-specific base substitution signature that is similar to COSMIC signature 3. In contrast, we detect different deletion phenotypes corresponding to specific HR mutants. The inactivation of BRCA2 or PALB2 leads to larger deletions, typically with microhomology, when compared to the disruption of BRCA1, RAD51 paralogs, or RAD54. Comparison with the deletion spectrum of Cas9 cut sites suggests that most spontaneously arising genomic deletions are not the consequence of double-strand breaks. Surprisingly, the inactivation of checkpoint kinases ATM and CHK2 has no mutagenic consequences. Analysis of tumor exomes with biallelic inactivating mutations in the investigated genes confirms the validity of the cell line models. We present a comprehensive analysis of sensitivity of the investigated mutants to 13 therapeutic agents for the purpose of correlating genomic mutagenic phenotypes with drug sensitivity.

Conclusion: Our results suggest that no single genomic mutational class shows perfect correlation with sensitivity to common treatments, but the contribution of COSMIC signature 3 to base substitutions, or a combined measure of different features, may be reasonably good at predicting platinum and PARP inhibitor sensitivity.

Keywords: Mutation signature, BRCA1, BRCA2, RAD51C, PALB2, RAD52, ATM, CHEK2, Microhomology deletion, PARP inhibitor

© The Author(s). 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Somatic mutations in cancer genomes efficiently characterize the DNA repair status of the cancer cells [1–3]. As a consequence, there is much interest in using genomic mutation patterns for the selection of treatments targeted at cells with specific DNA repair defects.

Germline mutations in the genes encoding the homologous recombination (HR) factors BRCA1 or BRCA2 predispose for breast and ovarian cancer [4, 5] and also play roles in the development of prostate, pancreatic, and stomach cancers [6]. The inactivation of BRCA1 or BRCA2 due to somatic mutations or BRCA1 promoter methylation is also observed in these tumor types [7–9]. The BRCA1/2 status of tumors is relevant for treatment selection, as a BRCA1/2 defect predicts sensitivity to platinum drugs and PARP inhibitors [7, 10, 11].

Tumors with biallelic inactivation of BRCA1 or BRCA2 possess genome-wide somatic single nucleotide variations (SNVs) with a distinct spectrum termed COSMIC signature 3, together with specific but different patterns of short insertions and deletion (indels), and of structural rearrangements [12, 13]. COSMIC signature 3 is one of a set of somatic base substitution signatures identified in cancer genomes [14, 15]. Experiments with isogenic cell lines provided causative evidence for the role of BRCA1 or BRCA2 defects in these mutagenic processes [16]. The existence of cancer cases with similar somatic mutation spectra but no BRCA1/2 mutations [12] raises the possibility that these carry mutations in genes of similar function and therefore may also benefit from treatments designed for BRCA mutant cancer [17]. Indeed, whereas only about 30% of ovarian cancer cases have BRCA mutations or promoter methylation [18], there exists a cohort of non-BRCA mutant ovarian cancer cases with a similar mutation spectrum and mutation burden to BRCA mutants [19], and PARP inhibitor treatment was found to be effective in a patient cohort without germline BRCA mutation as well [20].

Candidate genes to cause a BRCA-like phenotype are those that code for other non-essential factors of the HR pathway: the RAD51 paralogs RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3, which promote the formation of RAD51 subnuclear foci and also can remodel the RAD51 nucleoprotein filament [21, 22]; the binding partners of BRCA1 and BRCA2 including BARD1 [23], CtIP [24], and PALB2 [25]; and further HR factors including RAD54 [26] and RAD52 [27]. Checkpoint proteins involved in signaling the presence of DNA breaks, including ATM and CHK2, may have HR-related roles [28, 29]. Inherited mutations in several of these genes increase the risk of breast or ovarian cancer, including RAD51C, RAD51D, BARD1, PALB2, ATM, and CHK2 [30–32]. Consequently, clinical trials are underway to investigate the efficacy of PARP inhibitors on tumors with various subsets of non-BRCA DNA repair gene mutations (trial identifiers: NCT03344965, NCT02286687, NCT03375307).

As an alternative to the search for deleterious gene mutations, a genomic rearrangement-based phenotypic measure of HR defect has been developed that does not incorporate SNVs or short indels. The HRD score predicts response to platinum-containing neoadjuvant chemotherapy in triple-negative breast cancer [33], and also forms part of clinical diagnostic tests for using PARP inhibitors in ovarian cancer [34]. In addition, it has been an open issue whether BRCA1/2 deficiency/HRD is predictive only of PARP inhibitor/platinum sensitivity or of anthracyclines as well [35, 36]. The incorporation of genomic mutation signatures into the assessment of HR integrity has been suggested [12], and COSMIC SNV signature 3 was found to be associated with PALB2 and RAD51C mutations in breast cancer [3].

The aim of this study was to experimentally determine which HR or checkpoint gene defects cause somatic mutational processes akin to those seen in BRCA1- or BRCA2-deficient cells, and whether the presence of mutational signatures correlates with treatment sensitivity. Using an isogenic knockout cell line panel, we uncovered and analyzed the spontaneous mutagenic processes in HR-deficient cells and demonstrated that the inactivation of checkpoint kinases has negligible mutagenic consequences. SNV mutagenesis showed good but imperfect correlation with PARP inhibitor sensitivity, whereas the mutagenic processes were poor predictors of sensitivity to a range of common cancer cytotoxics.

Results
Increased single nucleotide substitution mutagenesis in a range of HR mutant cell lines
To investigate the genetic dependence of spontaneous mutagenesis, we assembled a collection of isogenic chicken DT40 cell lines harboring homozygous disruptions of each of eight key HR genes plus ATM and CHK2, which are key components of the DNA damage checkpoint. DT40 lymphoblastoma cells are the only isogenic system currently available to study null mutants in this range of genes, and these cells adequately reproduce human somatic mutagenic processes [16]. The RAD52−/− cell line was made for this study by deleting a 3323-bp region of the gene including exons 3–7. The derived cell lines were cultured for 50 days between two single cell cloning steps, and DNA was prepared for whole genome sequencing from each ancestral clone as well as three descendent clones per cell line (Fig. 1a, Additional file 1: Table S1). Base substitution mutations and small indels were identified by simultaneously analyzing all sequences together with IsoMut [37]. The mutations detected by IsoMut are unique to one sample, thereby providing an accurate catalog of
genetic changes that took place during the experiment (Additional file 1: Tables S2 and S3).

Compared to wild type cells, we observed an approximately seven to eightfold increase in base substitution (SNV) mutagenesis in BRCA1<sup>−/−</sup> and BRCA2<sup>−/−</sup> cells as shown previously [16]. We found a similarly elevated SNV mutagenesis in cell lines mutant for the RAD51 paralogs RAD51C, XRCC2, and XRCC3, and in PALB2<sup>−/−</sup> mutants (Fig. 1b, Additional file 1: Table S4). The mutation rate was threefold elevated in RAD54<sup>−/−</sup> mutants compared to the wild type, and the increase in mutation rate was highly significant in all seven mutants when compared to the wild type (<i>p</i> < 0.001, <i>χ</i><sup>2</sup> test on the summed counts with Bonferroni's correction for multiple comparison). No increase was seen in RAD52<sup>−/−</sup> cells. Surprisingly, we observed only a very moderate elevation of SNV mutation accumulation in the checkpoint-deficient ATM<sup>−/−</sup> and CHK2<sup>−/−</sup> cells, though the 1.5-fold change in ATM<sup>−/−</sup> cells was significant (<i>p</i> < 0.001).

A common base substitution signature describes mutagenesis in all HR-deficient cells

When viewed in the context of the neighboring nucleotides, similar triplet mutation patterns resulted from the disruption of BRCA1, BRCA2, PALB2, the RAD51 paralogs, and also RAD54 (Fig. 1c, Additional file 2: Figure S1). We summed the data by cell type and extracted de novo triplet mutation signatures using non-negative matrix factorization (NMF) on the 11 cumulative triplet mutation datasets. A factorization rank of two provided two de novo signatures, which could be used to reconstruct the mutation spectra with small errors (Fig. 2a, Additional file 2: Figure S2, Additional file 1: Table S5). The two signatures resulting from this unsupervised approach appeared to make good biological sense. One signature (termed Signature BG, for background) was similar to the mutation pattern of the wild type, and it was present to a very similar level in all mutants. An additional signature (Signature HRD, for HR deficiency) explained the increased
mutagenesis in all cell lines and can therefore be considered a general HR defect-specific triplet mutation signature. The inclusion in the NMF analysis of pre-existing mutations in the ancestral clones provided a very similar HRD-like signature (cosine similarity 0.995) and showed that the experimentally determined ongoing mutation rates do not correlate with past passaging (Additional file 2: Figure S3). Moreover, performing NMF on individual samples also resulted in near-identical HRD-like and BG-like mutation signatures (cosine similarities 0.998 and 0.987, respectively; Fig. 2a, Additional file 1: Table S5). In comparison to COSMIC version 2 signatures, Signature HRD is very similar to signature 3 (cosine similarity 0.940), whereas Signature BG shows more limited cosine similarities, but correlates best with signatures 1 and 5 using Spearman’s rank correlation (Fig. 2b, c, Additional file 1: Table S6). Signature HRD showed best correlation with SBS3 and the new SBS40 in version 3 of the COSMIC signatures (Additional file 2: Figure S4A, B). Interestingly, despite the similarity of signatures 3 and HRD, only 50–60% of mutations in the HR mutant cell lines were explained by signature 3 when attempting a deconstruction with COSMIC version 2 signatures 1, 3 and 5, probably due to the similarity of signatures 3 and 5 (Additional file 2: Figure S4C). Nevertheless, modeling the NMF process on differently sized sample sets drawn from pre-set mixtures of signatures 3 and 5 showed that the number of mutations detected in the HR-deficient cell lines allows the separation of such “featureless” signatures with only 5% mean absolute error (Additional file 2: Figure S5), confirming that SNV mutagenesis in the BRCA1, BRCA2, PALB2, and RAD51 paralog mutants is indistinguishable both in rate and spectrum.

**Disruption of the HR pathway at different stages gives rise to different short deletion phenotypes**

Few short insertions arose in the sequenced genomes, and the difference in the number of short insertions between the wild type and the various mutants was only significant in the case of XRCC2 ($p = 0.03$, $\chi^2$ test with Bonferroni’s correction) and PALB2 ($p = 0.044$) (Fig. 3a). In contrast, there was a highly significant ($p < 0.001$)
increase of short deletions upon the disruption of BRCA1, BRCA2, PALB2, RAD51C, XRCC2, or XRCC3, and a significant ($p = 0.039$) increase in the RAD54 mutant. The number of short deletions in RAD52−/−, ATM−/−, and CHK2−/− cells did not significantly differ from the wild type (Fig. 3b). To better understand how short deletions arise upon defective HR, we classified deletions based on their sequence context (Additional file 1: Table S4). In BRCA2−/− and PALB2−/− mutants, whose genomes contained the most deletions, over 50% of deletions showed at least 1 bp of microhomology between the ligated DNA ends (Fig. 3c). In all other HR mutants, deletions with no homology or deletions at repeat sequences were at least as common as the microhomology class. Deletions with microhomology were generally longer than those in the other categories (Fig. 3d) and the cumulative size distribution of all deletions also shows that BRCA2−/− and PALB2−/− have a similar phenotype that is distinct from those of other HR mutants (Fig. 3e). This phenotype of more, larger deletions with more common microhomologies is presumably connected to a joint function of the BRCA2/PALB2 complex. The phenotypes of the RAD51 paralogs were similar to each other; RAD54−/− had a weaker deletion phenotype, whereas BRCA1−/− displayed a surprising lack of short deletions in the 2–7-bp size range. In agreement with this analysis, a classification of indels into COSMIC version 3 short indel signatures [38] found the microhomology deletion dominated signature.
ID6 mainly in the BRCA2<sup>−/−</sup> and PALB2<sup>−/−</sup> datasets (Additional file 2: Figure S6). Thus, unlike in the case of SNVs, the disruption of the HR pathway at the level of different participating proteins results in distinct patterns of short genomic deletions.

**Spontaneously arising very short deletions are not the consequence of double-strand break repair**

To understand whether the different deletion phenotypes are caused by the influence of a partially disrupted HR pathway on DNA double-strand break (DSB) repair, we investigated the spectrum of mutation events at CRISPR/Cas9-induced blunt ended DSBs at two different genomic loci using amplicon sequencing. The majority of mutation events were deletions, alongside some insertions and some mixed events (Additional file 2: Figure S7). Unlike in the case of spontaneous deletions where deletion sizes varied, the size distribution of Cas9 DSB-induced deletions was very similar across all investigated HR mutants and the wild type cell line and resembled the spontaneous genomic deletion phenotype of BRCA2 and PALB2, with a median deletion size of approximately 4 bp (Fig. 3f). In contrast, we observed a reduction in the number and size of deletions in a Ku70<sup>−/−</sup> mutant cell line (Fig. 3f, g, black line), demonstrating the role of non-homologous end joining in shaping the outcome of DSB repair. The majority of spontaneous deletions observed in HR mutants are thus shorter than those observed at nuclease-induced DSBs. With the caveat that the Cas9 cut does not reproduce all types of potential spontaneous DSBs, these results suggest that the very short deletions are not the consequence of DSB repair but of a different process that is upregulated in the absence of HR proteins.

**Patterns of large-scale rearrangements differentiate HR mutants**

When searching for structural variations, we found a predominance of large deletions of a wide size range in BRCA2<sup>−/−</sup> and PALB2<sup>−/−</sup> cells, as well as in the three tested RAD51 paralog mutants (Fig. 4a, b, Additional file 1: Tables S4 and S7). The rearrangement phenotypes in these five cell lines could be best reconstructed with rearrangement signature 5 defined from the analysis of breast cancer genomes (Fig. 4c) [12]. Indeed, the size distribution of deletions and the presence of a few other types of non-clustered rearrangements in RAD51C<sup>−/−</sup>, XRCC2<sup>−/−</sup>, XRCC3<sup>−/−</sup>, BRCA2<sup>−/−</sup>, or PALB2<sup>−/−</sup> mutant cells closely resembled the predominant rearrangement signature of BRCA2-deficient breast tumors (Fig. 4d).

**HR-deficient cells show differential sensitivities to cancer cytotoxics**

The main incentive to investigate the mutagenic processes arising from the defect of a range of HR genes is to determine whether the observed mutation patterns may be predictive of therapeutic effect. To link mutational signatures to therapy, we measured the sensitivity of each experimental cell line to a wide range of commonly used cancer therapeutics (Fig. 5a, Additional file 1: Tables S8 and S9). The greatest hypersensitivity was seen in the case of the PARP inhibitors olaparib and talazoparib. Most HR mutant lines were also hypersensitive to platinum agents. A few cell lines, primarily BRCA1<sup>−/−</sup>, BRCA2<sup>−/−</sup>, and PALB2<sup>−/−</sup>, were also slightly sensitive to the anthracyclin doxorubicin, the topoisomerase II inhibitor etoposide, the topoisomerase I inhibitor SN-38 (the active form of irinotecan), and the alkylating agent temozolomide. RAD51 paralog mutants were also sensitive to PARP inhibitors, but to a lesser extent than the BRCA1/2 mutants, and showed no sensitivity to topoisomerase inhibitors. Interestingly, RAD52<sup>−/−</sup> mutants were most sensitive to platinum agents, whereas RAD54<sup>−/−</sup> mutants showed specific sensitivity to PARP inhibitors. The disruption of the DNA damage checkpoint in ATM<sup>−/−</sup> mutants did not sensitize cells to most tested agents. Even more unexpectedly, CHK2<sup>−/−</sup> mutant cells were less sensitive to platinum agents, PARP inhibitors, and topoisomerase inhibitors than the wild type line. We confirmed the reduced sensitivity of CHK2<sup>−/−</sup> cells to cisplatin, olaparib, and etoposide using a colony survival assay with short treatment duration to exclude the possibility that this result was influenced by potentially slower growth under the conditions of the cytotoxicity assay (Fig. 5d, Additional file 2: Figure S8).

The reliability of the cytotoxicity assay is highlighted by the excellent concordance of sensitivities to drugs with common mechanisms (Fig. 5b, c) and by the lack of sensitivity to drugs that do not cause DNA damage or target DNA repair, such as paclitaxel and hydroxyurea. The different pattern of sensitivities to oxaliplatin as compared to cisplatin and carboplatin supports findings that oxaliplatin kills cells through additional mechanisms independent of the DNA damage response [39]. Minimal sensitivities were seen to anthracyclins, restricted to a slight doxorubicin sensitivity of BRCA1, BRCA2, and RAD52 mutants.

**Mutation patterns in cancer genomes with HR gene defects**

We were able to detect specific mutational processes in genomes of isogenic cell line models with disrupted HR genes, but not in ATM<sup>−/−</sup> or CHK2<sup>−/−</sup> mutant cells. To test the utility of the mutation patterns in identifying cancers with defects in the same HR genes, we re-investigated a panel of tumor whole exome sequences in which cases of biallelic inactivation of HR-related genes were identified (Additional file 1: Table S10) [40]. In addition to BRCA1 and BRCA2, most tumors with biallelic inactivation of RAD51C or PALB2 showed a high
contribution of COSMIC signature 3 to the total exomic somatic SNV load (Fig. 6a). In further agreement with the cell line-based data, the majority of samples with ATM or CHK2 biallelic inactivation showed zero or very low contribution of signature 3. The median contribution of signature 3 to a matched random TCGA sample set with no inactivating mutation in the gene investigated in this study was zero, but there was a considerable number of mostly ovarian cancer samples which nevertheless contained mutations assigned to signature 3 (Fig. 6a, Additional file 2: Figure S9). Using the entire signature set from COSMIC version 3 resulted in lower sensitivity but higher specificity of detecting signature SBS3 in HR mutant samples (Additional file 2: Figure S10). The number of short (<50 bp) deletions showed no obvious differences between the various genotypes. These were dominated by 1 bp deletions at repeat sequences, some of which we suspect to be false mutation calls (Additional file 1: Table S10). However, there was a clear and specific increase of deletions with microhomology in BRCA2 and PALB2 mutant samples (Fig. 6b), and the cumulative size distribution of deletions also separates the BRCA2 and PALB2 phenotypes from the others (Fig. 6c), in remarkable agreement with the cell line-based data. These results confirm the cell line-based findings, suggesting that the contribution of signature 3 to the SNV load can be a useful biomarker for identifying tumors with RAD51 paralog or PALB2 loss-of-function alongside those with BRCA1 or BRCA2 defects, whereas deletions with microhomology identify BRCA2 and PALB2 defects.
Discussion

In this study, we used isogenic cell lines to detect similarities and differences in the patterns of spontaneous genomic mutagenesis resulting from the disruption of a range of HR genes, and also demonstrated that the inactivation of the DNA damage checkpoint does not give rise to a phenotype indicative of HR deficiency. A dataset derived from cytotoxicity measurements of common cancer therapeutics promotes further investigation for the evaluation of the predictive value of different genomic mutational signatures.

Three main types of mutational features are available for correlation with treatment sensitivity: base substitutions, short indels, and large rearrangements. Six of the tested mutants showed high rates of SNV mutagenesis characterized by signature 3, and \textit{RAD54} \(-/-\) cells had a similar, more moderate phenotype. According to the cytotoxicity results, the contribution of signature 3 is therefore a reasonable overall predictor of PARP inhibitor and platinum sensitivity. However, the lower sensitivity of \textit{RAD51} paralog mutants compared to \textit{BRCA1} \(-/-\), \textit{BRCA2} \(-/-\), and \textit{PALB2} \(-/-\) suggests a lower predictive value of SNV signatures for PARP inhibitor treatment. Deletion patterns can most accurately identify defects of \textit{BRCA2} and \textit{PALB2}, also confirmed in tumor genomes; therefore, a high proportion of deletions with microhomologies may be a good predictor of treatment with PARP inhibitors, cisplatin or carboplatin. Structural variations with rearrangement signature 5 specifically identify cells with dysfunctional \textit{BRCA2}, \textit{PALB2}, or \textit{RAD51} paralogs; therefore, their presence also correlates with sensitivity to PARP inhibitors and platinum.

There are two caveats with using the investigated genomic features for prediction of drug sensitivity. False positives may arise due to different sensitivities of cell lines with the same genomic features, e.g., in the case of...
RAD51C versus BRCA2 mutants. False negatives arise due to the lack of certain genomic features in sensitive cell lines, as in the case of the lack of signature 5 rearrangements in BRCA1 mutant cells, which are nevertheless very sensitive to PARP inhibitors. The use of a linear combination of the strength of mutational processes, and the incorporation of a rearrangement signature characteristic of BRCA1 mutant cells led to an improved classification of BRCA1/2 deficiency, named HRDetect [41]. The setup of our cell line-based experiments did not produce a sufficient number of large rearrangement events to meaningfully calculate HRDetect scores, but the results suggest that HRDetect will successfully identify cells and tumors with defects in PALB2, RAD51 paralogs, or RAD54. Whereas this approach can lead to the reduction of false negatives, the problem of false positives may be inherent to the different mechanistic roles of the investigated proteins in the HR pathways.

Genomic deletion data may help understanding the distinct functions of HR proteins. The majority of deletions in wild type cells are very short, with a median length of 1 bp. The same is true in BRCA1, RAD54, and RAD51 paralog mutants, though an appearance of longer deletions with microhomology is also seen. In contrast, longer deletions with microhomology dominate in BRCA2 and PALB2 mutants, and these closely resemble the spectrum of deletions at Cas9-induced DSBs in wild type and HR mutant cells. It therefore seems that HR proteins function in preventing two distinct mutagenic processes that give rise to genomic deletions. A replicative process may give rise to the very short (1–2 bp) deletions as well as SNVs with an HRD spectrum, and all investigated HR proteins antagonize this apart from RAD52. The more moderate SNV and deletion phenotype of RAD54 may simply be due to redundancy with RAD54B [42]. Conversely, DSB repair by non-homologous end joining is likely to produce the observed longer (3–20 bp) deletions with microhomology. The
results therefore suggest that BRCA2 and PALB2 have a
distinguished role in preventing the formation of spontan-
eous DSBs, possibly through protecting stalled and re-
versed replication forks from nucleolytic cleavage [43, 44].

The near-complete lack of mutagenic consequences of
ATM or CHK2 disruption is surprising and suggests that
the main function of this DNA damage checkpoint me-
chanism is not the facilitation of correct repair, at least in
cells with a moderate amount of endogenous DNA dam-
age. This is in agreement with reports showing no impair-
ment of HR repair upon CHK2 inactivation [45, 46].

Indeed, our results and further recent data did not show an
increased contribution of signature 3 mutations to
somatic SNVs in ATM-deficient tumors [47, 48]. Instead,
the main relevance of the pathway to tumor cells may be
cell cycle arrest and p53-mediated apoptosis, explaining the
mutual exclusivity of ATM and TP53 inactivation in breast cancer [47]. The ATM or CHK2 mutant cell lines
typically also did not show sensitivity to DNA damaging
agents and PARP inhibitors, and despite promising earlier
results, olaparib did not lead to improved overall survival
for patients with ATM-negative gastric tumors in a phase
3 trial [49, 50]. Taken together, the mutagenicity and drug
sensitivity results argue against making a connection be-
tween HR-deficient and ATM/CHK2-deficient cancers.

Conclusion
In conclusion, our results suggest that no single genomic
mutational class shows perfect correlation with sensitivity
to common treatments, but the contribution of COSMIC
signature 3 to SNVs, or a combined measure of different
features, may be reasonably good at predicting platinum
and PARP inhibitor sensitivity. The mutagenic processes
result from loss of integral HR pathway components;
therefore, cancers with non-BRCA HR defects, such as
germline or somatic mutations in PALB2, RAD51B,
RAD51C, or RAD51D, or their inactivation through pro-
moter methylation [3], would also receive a positive treat-
ment prediction. However, if the tested cell lines accurately
model the relevant tumor tissues, the lower sensitivity of
RAD51 paralog mutants to PARP inhibitors may predict a
reduced clinical response in tumors with the correspond-
ing gene defects. The employed p53-negative lymphoid cell
line model clearly has limitations [51, 52], but the multiple
levels of agreement between cell line and tumor-derived
mutation patterns encourage the further use of isogenic
cell line models to decipher the complex mutational pro-
cesses in human cancer.

Methods

Cell culture

The following DT40 cell lines were used: wild type,
BRCA1/−/−, and BRCA2/−/− as used in [16]; PALB2/−/− [53];
RAD51C/−/−, XRCC2/−/−, and XRCC3/−/− [22]; RAD54/−/−
(gene name RAD54L) [54]; ATM/−/− [55]; and CHK2/−/−
(gene name CHEK2) [56]. RAD52/−/− mutant cells were
generated by homologous gene targeting, replacing the
genomic region from the NdeI restriction site upstream of
exon 3 until the BamHI restriction site downstream of
exon 7 on each allele with blasticidin and hygromycin
selection cassettes, respectively. All cell lines and all gene
mutations were verified using the whole genome sequence
cells. Cells were grown at 37 °C under 5% CO2 in RPMI-
1640 medium supplemented with 7% fetal bovine serum,
3% chicken serum, and 50 μM 2-mercaptoethanol. PX458
(Addgene plasmid #48138) [57] transiently expressing
Cas9, GFP, and a guide RNA was transfected into 600,000
cells using a Nucleofector 4D instrument (Lonza) with
program CN-150. GFP+ cells were sorted 24 h later, and
after a further 24 h, by which time the arising mutation
spectrum is expected to be stable [58], the regions of the
targeted events were amplified from genomic DNA prepa-
rations using indexed PCR primers.

DNA sequencing and mutation calling

Whole genome sequencing on Illumina HiSeq X Ten in-
struments (2 × 150 bp paired end) to 30 GB coverage per
cell clone was done at Novogene, Beijing, China. A mean
coverage of 27× was achieved in the near-diploid DT40
genome [52]. The alignment of reads was done as de-
scribed, using the Galgal4.73 reference genome (16). Inde-
pendently arising SNVs and short indels were identified
using IsoMut, run on all samples together with default set-
tings [37]. The output was post-filtered such that no more
than five SNVs and one indel were detected in the ancestral
clones, as mutations detected as unique in these samples
provide an internal control for false positives. To identify
mutations in each ancestral clone that formed since the last
common ancestor with the other cell lines, IsoMut was re-
run with the omission of the descendental clones of the
respective genotype. Mutations in protein coding se-
quencies of ancestral clones are presented in Addi-
tional file 1: Table S11. Short deletions were classified
as repeat if the deleted sequence was present in at least two
tandem copies and as microhomology if the sequence at
the two breakpoints contained at least 1 bp of homology.
Structural variations were detected using CREST [59] with
post-filtering steps. The post-filtering of the CREST’ output
utilized three filters to deem a structural event valid: both
breakpoints had to be unique among the samples, both
breakpoints had to be covered by reads in all of the sam-
ples, and the structural variant had to be supported by at
least five soft-clipped reads. CRISPR-targeted amplicons
were sequenced on Illumina HiSeq 2500.

Signature analysis

Individual SNV spectra were averaged for each genotype. De
novo NMF decomposition and fitting of triplet
signatures was performed using the R package *MutationalPatterns* [60]. During de novo NMF of experimental data, an optimal component number of two was chosen based on the cophenetic correlation coefficient and the residual sum of squares values (Additional file 2: Figure S2) and the same settings were used on simulated data (Additional file 2: Figure S5). Signature deconstruction was performed using the *deconstructSigs* R package [61] using version 2 of the COSMIC signatures [15] unless otherwise stated. For comparisons to COSMIC triplet signatures, DT40 triplet signatures were adjusted by multiplying with the ratio of triplet occurrences in the human and chicken genomes [62]. COSMIC version 3 short indel classification (Additional file 1: Table S12) was performed using a custom script that used the IsoMut indel output list (Additional file 1: Table S3) as its input. For the structural variation signature analysis, we used the rearrangement signature set defined by [12]. Potential clustered events were detected using the R package *copynumber*, using a piecewise constant fitting method with parameters $k_{min} = 10$ and $\gamma = 25$. After classifying the indels and the structural variants, the signature contributions were calculated by non-negative least squares regression using the R package *pracma*.

**CRISPR-based DS8 repair analysis**

Two loci were targeted: exon 6 of the *HMBS* gene (gRNA directed against chr24:40917-40636) and exon 1 of the *XPC* gene (gRNA directed against chr12:10787326-10787346). The gRNA sequences targeting locus 1 and locus 2 were GCAACATGGTAAAGGCCAGG and GATCTGCTCGCCGCTATGGGC, respectively. To amplify the DNA in the region surrounding the targeted sites, we used primers gacNNNNNNCCACCTGCAAACATTAGTCC and gacNNNNNCTGTTCAGTGTTGTGACTGC for locus 1 and gacNNNNNNGTGCCCGCATCTTTCAACC and gacNNNNNNCCGGGCGCCCTTTCGGC for locus 2, where underlined letters denote flanking sequences and N's denote sample-specific barcodes. The ampiclon sequencing reads were first preprocessed with Trimmomatic [63] to remove Illumina sequencing adapters and sequences of low base quality. The read pairs were merged using FLASH2 [64] with maximal overlap length set to 150 and maximal mismatch density set to 0.05. The merged ampiclons were aligned against the theoretical ampiclon sequence using the global pairwise aligner Needle from the EMBOSS toolset [65] and the sequence alterations found in each ampiclon were summarized and visualized with a custom Python script.

**Sensitivity measurements**

For cytotoxicity assays, 1000 cells per well in 384-well plates were incubated with cytotoxic drugs (Additional file 1: Table S9) at a range of concentrations. Cell viability was measured after 72 h using PrestoBlue (Thermo Fisher) and an EnSpire plate reader (Perkin-Elmer). Three technical replicates were averaged per experiment. Data were normalized to untreated cells; curves were fitted with the GraphPad Prism software using the sigmoidal dose–response model. Curve fit statistics were used to determine IC$_{50}$ values. Colony survival assays were performed by plating cell dilutions in medium containing 1% methylcellulose following 1-h cisplatin treatments or 24-h treatments with olaparib or etoposide, and counting the emerging cell colonies.

**Analysis of TCGA samples**

Whole exome sequencing data of samples from a wide variety of tissues were obtained based on the pipeline described by Riaz and colleagues [40] from the Broad GDAC Firehose portal. Samples with fewer than 100 somatic SNVs were excluded from analysis. Mutational annotation format files were processed with the R software environment. For each investigated HR-related gene, only samples with germ line or somatic biallelic pathogenic mutations, either with loss of heterozygosity or with compound heterozygosity, were considered as confirmed pathogenic variants. Samples with only monoallelic pathogenic mutations or with variants of uncertain significance but no confirmed pathogenic mutations were excluded. For negative control, samples with neither pathogenic mutations nor variants of uncertain significance in any of the investigated genes were selected. Deconstruction of mutational signatures to the 30 COSMIC signatures was performed with the *deconstructSigs* R package [61].

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13059-019-1867-0.

**Additional file 1:** Table S1. Provides general sequencing statistics.

**Tables S2** and **S3.** Contain a catalogue of all detected SNVs and indels, respectively. Table S4. Contains a summary of all detected genetic alterations.

**Table S5.** Provides the numerical values of de novo SNV signatures.

**Table S6.** Contains numerical data for cosine similarity and Pearson correlation values between SNV signatures. Table S7. Lists all detected and post-filtered SVs.

**Table S8.** Provides all measured IC50 doses on all cell lines. Table S9. Lists the sources of all chemotherapeutic drugs used in this study. Table S10. Provides the identifier, genotype, mutation data and SNV signature contributions of analysed TCGA samples.

**Figure S1.** Shows SNV spectra normalised to the frequency of each triplet occurrence. Figure S2. Shows the NMF output used for defining signatures HRD and Bg. Figure S3. Shows the derivation of SNV signatures on a dataset that includes pre-existing mutations in the ancestral clones. Figure S4. Correlates detected SNV spectra and signatures with COSMIC SNV signatures. Figure S5. Shows a simulation of separating featureless SNV signatures. Figure S6. Shows a deconstruction of detected indel datasets into indel signatures. Figure S7. Shows the results of ampiclon sequencing across Cas9 cut sites. Figure S8. Shows drug sensitivity measurements on ancestral and descendant clones. Figures S9 and S10. Show the contribution to the SNV load of TCGA samples of COSMIC v2 and v3 SNV signatures, respectively.

**Additional file 2:** Figure S1. Shows SNV spectra normalised to the frequency of each triplet occurrence. Figure S2. Shows the NMF output used for defining signatures HRD and Bg. Figure S3. Shows the derivation of SNV signatures on a dataset that includes pre-existing mutations in the ancestral clones. Figure S4. Correlates detected SNV spectra and signatures with COSMIC SNV signatures. Figure S5. Shows a simulation of separating featureless SNV signatures. Figure S6. Shows a deconstruction of detected indel datasets into indel signatures. Figure S7. Shows the results of ampiclon sequencing across Cas9 cut sites. Figure S8. Shows drug sensitivity measurements on ancestral and descendant clones. Figures S9 and S10. Show the contribution to the SNV load of TCGA samples of COSMIC v2 and v3 SNV signatures, respectively.

**Additional file 3.** Review history.
Acknowledgements
The authors wish to thank David Gillespie for the CHK2–/– cell line.

Review history
The review history is available as Additional file 3.

Peer review information
Yixin Yao was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Authors’ contributions
ALR, ZS, and DS conceived the study, DS made the RAD52 mutant. HG performed the long-term cell culture. OR, Stöth, DC, BS, and GS designed and performed the cytotoxicity experiments. SS, CK, AP, and HG designed and performed, and AP evaluated the CRISPR ampiclon sequencing experiments. AP and EN performed the bioinformatic analyses. STakeda provided the cell lines and advice. DS wrote the manuscript. All authors analyzed the data and read and approved the final manuscript.

Funding
This work was supported by the Research and Technology Innovation Fund of Hungary (K_124881 to DS, FK_16-1-2016-0005 to DS and GS, PD_121381 to BS, KTA_NAP_13-2014-0021 and NAP2-2017-1.2.1-NKP-0002 to ZS) and the Breast Cancer Research Foundation (BCFR-18-137 to ALR, BCFR-18-159 to ZS). Stakeda is a recipient of the Core-to-Core Program of JSPS.

Availability of data and materials
Whole genome sequence data generated in the course of this study is available from the European Nucleotide Archive under study accession number PRJEB33881 [66]. Custom scripts are available at the github repository https://github.com/szutsgroup/hrmutants [67]. Identifiers of the analyzed TGCA samples are listed in Additional file 1: Table S10. Mutation annotation files that formed the basis of the TCGA analysis can be downloaded from the Broad GDAC Firehose portal using instructions provided by Riaz et al. [40].

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt 2, Budapest H-1117, Hungary.
2Department of Oncology, University of Szeged, Szeged, Hungary.
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
5Department of Radiation Genetics, Kyoto University Medical School, Kyoto 606-8501, Japan.
6Department of Cancer Research, Medical University Vienna, Vienna, Austria.
7Computational Health Informatics Program (CHIP), Boston Children’s Hospital, Boston, MA, USA.
8Harvard Medical School, Boston, MA, USA.
9Danish Cancer Society Research Center, Copenhagen, Denmark.
10SE-NAP, Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
11Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 7 May 2019 Accepted: 28 October 2019
Published online: 14 November 2019

References
1. Zhao H, Thienpont B, Yesilyurt BT, Moise M, Reumers J, Coenegrachts L, et al. Mixmatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. Elife. 2014;3:e02725.
2. Kim J, Mounu KW, Polak P, Braunstein LZ, Kamburov A, Tiao G, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600–6.
3. Polak P, Kim J, Braunstein LZ, Karic R, Haradhavala NJ, Tiao G, et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017;49(10):1476–86.
4. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7(12):937–48.
5. Altiparmak F, Fereday S, Meldrum C, deFazio A, Emmanouel M, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA-mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2664–63.
6. Cavanagh H, Rogers KM. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015;13(1):16.
7. Pennington KP, Walsh T, Harrell MJ, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–75.
8. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
9. Hennessy BT, Timins KM, Carey MS, Gutin A, Meyer LA, Flaxe DD, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570–6.
10. Farahani L, Graziani G. Role of BRCA mutations in cancer treatment with poly (ADP ribose) polymerase (PARP) inhibitors. Cancer. Basel. 2018;10(12):487.
11. Byers LA. Morphology and the relevance of tumor mutational differences. Cancer Epidemiol Biomark Prev. 2013;22(3):415–21.
12. Zamborszky J, Szikriszt B, Gervai JZ, Pipek O, Poti A, Krystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene. 2017;36(6):746–55.
13. Pilk P, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759–71.
14. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2011;5(11):1137–54.
15. Dong F, Davineni PK, Herstedt J, Beck AH. A BRCA1/2 mutational signature and survival in ovarian high-grade serous carcinoma. Cancer Epidemiol Biomark Prev. 2016;25(11):1511–6.
16. Mirza MR, Monk BJ, Herstedt J, Oza MK, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.
17. Taylor MRG, Spirek M, Chaurasia KR, Ward JD, Carzagna R, Xu Y, et al. Rad51 paralog remodel pre-synaptic Rad51 filaments to stimulate homologous recombination. Cell. 2015;162(2):271–86.
18. Takata M, Sakasick K, Gervaz J, Pipek O, Poti A, Krystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene. 2017;36(6):746–55.
19. Pilk P, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759–71.
20. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2011;5(11):1137–54.
21. Dong F, Davineni PK, Herstedt J, Beck AH. A BRCA1/2 mutational signature and survival in ovarian high-grade serous carcinoma. Cancer Epidemiol Biomark Prev. 2016;25(11):1511–6.
22. Mirza MR, Monk BJ, Herstedt J, Oza MK, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.
23. Taylor MRG, Spirek M, Chaurasia KR, Ward JD, Carzagna R, Xu Y, et al. Rad51 paralog remodel pre-synaptic Rad51 filaments to stimulate homologous recombination. Cell. 2015;162(2):271–86.
24. Takata M, Sakasick K, Gervaz J, Pipek O, Poti A, Krystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene. 2017;36(6):746–55.
25. Pilk P, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25:3759–71.
28. Parameswaran B, Chiang HC, Lu Y, Coates J, Deng CX, Baer R, et al. Damage-induced BRCA1 phosphorylation by Chk2 contributes to the timing of end resection. Cell Cycle. 2015;14(3):437–48.

29. Lee JH, Pauli TT. ATM activation by DNA and DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science. 2005;308(5721):551–4.

30. Antoniou AC, Casadei S, Heikkilä T, Barrowdale D, Pylykas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.

31. Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, et al. Breast and ovarian cancer penetrance estimates derived from germline multiplegene sequencing results in women. JCO Precision Oncol. 2017;1(1):1–12.

32. Song H, Dicks SJ, Tyers JP, Interrappa MG, Hayward J, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol. 2015;33(26):2901–7.

33. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73.

34. Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, et al. Candidate biomarkers of PARP inhibitor sensitivity in cancer beyond the BRCA genes. Br J Cancer. 2018;119(1):401–9.

35. Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, et al. BRCA1 as a biomarker for predicting prognosis and response to anthracycline-based adjuvant chemotherapy for patients with triple-negative breast cancer. PLoS One. 2016;11(12):e0167016.

36. Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol. 2015;26(3):523–8.

37. Pipek O, Ribli D, Molnár J, Póti A, Krzystanek M, Bodor A, et al. Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. BMC Bioinform. 2017;18(1):73.

38. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Ng AW, Wu Y, et al. The Cancer Genome Atlas Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Med. 2017;23(4):517–28.

39. Pipek O, Ribli D, Molnár J, Póti A, Krzystanek M, Bodor A, et al. Fast and accurate mutation detection in whole genome sequences of multiple isogenic samples with IsoMut. BMC Bioinform. 2017;18(1):73.

40. Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of mutational signatures in cancer genomes. bioRxiv. 2019;322859. https://doi.org/10.1101/322859.

41. Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23(4):461–71.

42. Riaz N, Blecau P, Lim RS, Shen R, Higginson DS, Weinhold N, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nat Commun. 2017;8(1):857.

43. Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is an algorithm for predicting mutation response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22(15):3764–73.

44. Kolinjivadi AM, Sannino V, De Antoni A, Zadorozhny K, Kilkenny M, Techer F, et al. COMPASS2: a web server for comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10(1):33.

45. Bezzubova O, Silberglett A, Yamauchi-Iwai Y, Takeda S, Buerstedde JM. Reduced X-ray resistance and homologous recombination frequencies in a RAD54−/− mutant of the chicken DT40 cell line. Cell. 1997;89(2):185–93.

46. Takao N, Kato H, Mori R, Morrison C, Sonoda E, Sun X, et al. Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene. 1999;18(50):7002–9.

47. Rainey MD, Black EJ, Zachos G, Gillespie DA. Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase. Oncogene. 2008;27(17):9896–906.

48. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308.

49. Taheri-Ghahfarokhi A, Taylor BM, Nitsch R, Lunder A, Cavalli AL, Madesky-Bengtson K, et al. Decoding non-random mutational signatures at Cas9 targeted sites. Nucleic Acids Res. 2018;46(16):8417–34.

50. Wang J, Mullighan GC, Easton J, Roberts S, Heatley SM, Ma J, et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011;8(8):652–4.

51. Blockiz F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10(1):33.

52. Rosenthal R, McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 2016;17:31.

53. Szakmary B, Poti A, Pipek O, Krzystanek M, Kanu N, Molnar J, et al. A comprehensive survey of the mutative impact of common cancer cytotoxicities. Genome Biol. 2016;17:99.

54. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.

55. Magoo T, Salberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–63.

56. Rice P, Longden I, Blesby A. EMBOSS: the European molecular biology open software suite. Trends Genet. 2000;16(5):276–8.

57. Pötö A, Szüts D. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. PLoS33877. European Nucleotide Archive. 2019. https://www.ebi.ac.uk/ena/data/view/PRJEB33877.

58. Pötö Á, Szüts D. Hmutants supplementary scripts. Github. 2019. https://github.com/szutsgroup/hrmutants.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions